Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Advances Amgen's mission to serve patients with rare disease medicines
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
APP13007 is a novel aqueous nanosuspension formulation for the treatment of inflammation and pain following ocular surgery
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
ProBioGen previously developed the cell line and the manufacturing process and provided the initial clinical material for ImmunOs' innovative biologic.
Subscribe To Our Newsletter & Stay Updated
